CoChat

Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis

Juliusson, Gunnar, Imam, Mohamad, Björnsson, Einar S., Talwalkar, Jayant A., Lindor, Keith D. · 2016 · Scandinavian Journal of Gastroenterology

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Objectives Antimitochondrial antibodies (AMA) are a sensitive and specific marker for primary biliary cirrhosis (PBC). AMAs are present in 95% of patients with PBC. However, 5% do not have AMAs and data on these patients is scarce. We aim to evaluate the long-term outcomes of patients with AMA negative PBC. Methods A retrospective chart review of 71 AMA negative PBC patients. Disease presentation, laboratory results, and clinical endpoints were recorded. AMA negative patients were matched on year of diagnosis to a control group of 71 AMA positive patients. Results Ninety-six percent of the AMA negative patients were of female gender with a median age at diagnosis of 55 years and a length of follow-up of 7.5 years vs. 86% females, a median age of 56 and a follow-up of 8.3 years in the control group. Mean total bilirubin and alkaline phosphatase levels were 0.7 mg/dL vs. 0.6 and 570 U/L vs 341, in AMA negative vs. AMA positive patients at presentation, respectively (p = NS). AMA negative patients did not differ in terms of age, serum IgM levels, ANA status, or length of follow-up. Notably, AMA negative patients had a significantly reduced survival free of liver-related complications including transplantation and death compared to AMA positive patients (p = 0.0182). Conclusion In this large experience, AMA negative PBC patients had a significantly worse prognosis compared to AMA positive PBC patients. The reason for the difference in prognosis is unclear, as it may be true diffe…

Overview

Integrity signals

Registry

Crossref · 10.3109/00365521.2015.1132337

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Research works printed but not linked: 3

  1. Lacerda MA, 1995, Am J Gastroenterol, 90, 247
  2. Tsou Y-K, 2003, Chang Gung Med J, 26, 323
  3. Zhang F-K, 2004, Hepatobiliary Pancreat Dis Int, 3, 288

Cited by

See all 58

Metadata

Authors
Juliusson, G., Imam, M., Björnsson, E. S., Talwalkar, J. A., & Lindor, K. D.
Affiliations
  • University of Iceland (IS)
  • Mayo Clinic (US)
  • Arizona State University (US)
Corresponding author
Talwalkar, Jayant A.
Venue
Scandinavian Journal of Gastroenterology
Published
2016-01-18
Volume
51
Issue
6
Pages
745-752
ISSN
  • 0036-5521 (ISSN-L)
  • 1502-7708
OpenAlex
W2290429686
Cited by
47
References
36
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 3 · 2018: 4 · 2017: 5 · 2016: 1
FWCI
3.13
Type
journal article
Language
en
Open access
closed
Locations
  • Scandinavian Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Hirsla (Landspítali University Hospital) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
Keywords
primary biliary cirrhosis, antimitochondrial antibodies, long-term outcomes, prognosis, survival, liver transplantation, liver-related mortality
MeSH terms
Adult, Aged, Aged, 80 and over, Autoantibodies, Female, Follow-Up Studies, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Prognosis, Retrospective Studies, Biomarkers, Case-Control Studies, Liver Transplantation, Disease Progression, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. https://app.cochat.ai/papers/10.3109/00365521.2015.1132337
The paper
Juliusson, G., Imam, M., Björnsson, E. S., Talwalkar, J. A., & Lindor, K. D. (2016). Long-term outcomes in antimitochondrial antibody negative primary biliary cirrhosis. Scandinavian Journal of Gastroenterology. https://doi.org/10.3109/00365521.2015.1132337

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.